Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Multiple myeloma science from EHA 2019

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Multiple myeloma science from EHA 2019 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

CAR T-cell therapy for treating acute leukaemia

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

CAR T-cell therapy for treating acute leukaemia ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia ( Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA )

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

$CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )$

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer